In a move to strengthen its cell therapy offerings, the American pharmaceutical giant GE healthcare recently acquired Asymptote – a UK-based medical research firm having expertise in cold chain space. The newly acquired also holds an impressive portfolio of advanced cryochain technology, particularly for sensitive cellular therapies.
GE Healthcare is likely to benefit from this deal, as it will now be able to use Asymptote’s new age cryopreservation technology for storing of cellular materials and ensure safer production and delivery of cell therapies. Cold chain management of regenerative cell therapy remains an optimistic area for biopharmaceutical companies. Besides, the next-generation cryopreservation engineering technologies are replacing the conventional methods having inherent drawbacks. Further, the arrival of advanced cell therapies in the market is attracting more investments in this segment. Over the past couple of years, the popularity of regenerative medicines and cell therapies has surged substantially in the medical world owing to their increased efficiency and higher patient satisfaction.
GE Healthcare formerly headquartered in Chicago is predominantly known for its exponential capabilities in medical imaging and information technologies, patient monitoring systems, biopharmaceutical manufacturing, drug discovery and performance solutions services. Indeed, with this acquisition, the company will increase its visibility in cold chain business as well.
Asymptote’s combined suite of cryochain consumable, software and hardware comply with all the latest CGMP regulations for delivering of sensitive products. The company utilises unique indigenously developed technologies to maintain the effectiveness of cellular therapies by allowing ultra-low-temperature cooling throughout the manufacturing process till the time it is administered to the patient in clinical settings. For instance, Asymptote’s existing VIA FreezeTM range offers liquid nitrogen-free cryopreservation, while the VIA ThawTM series, which is to be available soon in the market will allow physicians to thaw deeply frozen cells using a dry conduction (water-free) process. Likewise, the company has a web-based software my.Cryochain, which is a digital platform developed to support cell therapy companies during cryopreservation and thawing procedures. The software uses a special VIA Freeze and VIA Thaw system that synchronises freezing and melting process. Moreover, the software offers a standardised program across multiple sites, increasing process visibility.
Asymptote will provide an opportunity for GE Healthcare to access a wider pool of audience as well as a better platform to display its latest products and allow the company to further ramp-up its product developmental activities. Undoubtedly, the acquisition will also boost GE Healthcare’s ambitions of offering cutting age cellular therapies to cure chronic ailments such as cancer and diabetes. In addition, Asymptote’s impressive product bandwidth is anticipated to provide the required impetus to GE Healthcare’s market aspirations going forward. As the competition in the market continues to grow fierce, manufacturers aim to industrialise cell therapy production and create an environment that ensures high-quality and reliable cold chain services for their clients.